Diabetes Self-Management Blog

People who use a specific combination of antidepressants have been found to be at increased risk for Type 2 diabetes, according to a study by researchers at the University of Alberta, Edmonton.

As reported at MedPage Today, the study found that people who took both a tricyclic antidepressant and a selective serotonin reuptake inhibitor (SSRI) were almost twice as likely to develop Type 2 diabetes as those who took only a tricyclic antidepressant. The study was based on medical records in the Canadian province of Saskatchewan and examined 2,391 adults who had been treated for depression.

Since the study was not a randomized experiment, it cannot show that the tricyclic/SSRI drug combination is responsible for increasing the risk of Type 2 diabetes, only that the two are related. It is possible that people who were prescribed both types of antidepressants already had a greater diabetes risk (which may be related to having more severe depression). So while these results cannot suggest any changes to the treatment of depression, they do indicate the need for diabetes screening among people who take these drugs.

A summary of the study is available at ScienceDirect.

This blog entry was written by Editorial Assistant Quinn Phillips.

POST A COMMENT       
  

Comments
  1. There are no comments at this time.


Post a Comment

Note: All comments are moderated and there may be a delay in the publication of your comment. Please be on-topic and appropriate. Do not disclose personal information. Be respectful of other posters. Only post information that is correct and true to your knowledge. When referencing information that is not based on personal experience, please provide links to your sources. All commenters are considered to be nonmedical professionals unless explicitly stated otherwise. Promotion of your own or someone else's business or competing site is not allowed: Sharing links to sites that are relevant to the topic at hand is permitted, but advertising is not. Once submitted, comments cannot be modified or deleted by their authors. Comments that don't follow the guidelines above may be deleted without warning. Such actions are at the sole discretion of DiabetesSelfManagement.com. Comments are moderated Monday through Friday by the editors of DiabetesSelfManagement.com. The moderators are employees of Madavor Media, LLC., and do not report any conflicts of interest. A privacy policy setting forth our policies regarding the collection, use, and disclosure of certain information relating to you and your use of this Web site can be found here. For more information, please read our Terms and Conditions.


What We're Reading
Metformin Study Currently Recruiting (08/19/14)
Back In Session: Diabetes at School (08/11/14)
BMX Camp for Kids With Type 1 Diabetes (07/31/14)
DiabetesSisters Weekend for Women in Los Angeles (07/22/14)

Oral Medicines
New Metformin Combo Drug Approved for Type 2 Diabetes (08/13/14)
FDA Approves New Oral Drug for Type 2 Diabetes (08/07/14)
New SGLT Drugs Coming (07/23/14)
Metformin More Effective in African-Americans (07/10/14)

Emotional Health
Diabetes Distress and Depression (07/09/14)
What Is Hardest About Diabetes for You? (05/28/14)
Diabetes Friends (05/06/14)
Attraction and Repulsion (04/24/14)

Diabetes Research
Metformin Study Currently Recruiting (08/19/14)
FDA Approves New Oral Drug for Type 2 Diabetes (08/07/14)
Shift Work Tied to Increased Type 2 Diabetes Risk (07/31/14)
High-Salt Diet Doubles Heart Risk in Type 2 Diabetes (07/25/14)

 

 

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.